ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
February 26, 2020 07:00 ET
|
ProQR Therapeutics N.V.
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal...
ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
July 02, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
March 11, 2019 08:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
January 29, 2019 08:30 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
January 02, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
December 04, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
February 12, 2018 07:00 ET
|
ProQR Therapeutics N.V.; Foundation Fighting Blindness
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting...
ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
September 05, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the...
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
May 01, 2017 07:00 ET
|
ProQR Therapeutics
Key updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA 10. The company has recently received IND clearance to start clinical...